Colivelin Evidence Guide
Evidence for Colivelin is too preliminary to support a research protocol with confidence. All data comes from mouse models of Alzheimer's disease, with no human pharmacokinetic data, no safety studies, and no clinical trials. Of the Cognitive & Nootropic compounds in this library, cerebrolysin has far more clinical evidence as a starting point for neuroprotective research.
Our Take
Evidence for Colivelin is too preliminary to support a research protocol with confidence. All data comes from mouse models of Alzheimer's disease, with no human pharmacokinetic data, no safety studies, and no clinical trials. Of the Cognitive & Nootropic compounds in this library, cerebrolysin has far more clinical evidence as a starting point for neuroprotective research.
- Best for
- CNTF/humanin hybrid neuroprotection mechanistic research (mouse only)
- Evidence grade
- Level D
- Confidence
- Low
- Starting point
- No established human protocol
Benefits and Evidence
- Neuroprotection Against Amyloid-Beta: Level D, mostly non-human evidence - Colivelin protects neurons from amyloid-beta 1-42 and amyloid-beta 25-35 toxicity at femtomolar to picomolar concentrations in culture, far more potent than either component peptide alone.
- Cognitive Rescue in AD Models: Level D, mostly non-human evidence - Intracerebroventricular administration of Colivelin rescued spatial memory deficits in multiple AD mouse models (3xTg, amyloid-beta-injected), restoring Morris water maze performance to near-normal levels.
- Anti-Apoptotic Activity: Level D, mostly non-human evidence - Colivelin inhibits Bax-mediated mitochondrial apoptosis, reduces caspase-3 activation, and maintains mitochondrial membrane potential under neurotoxic conditions.
Side Effects and Warnings
- No adverse effects reported in published animal studies
- Unknown human safety profile
- Potential for unexpected effects from dual-pathway activation
- All data is preclinical - no human studies exist
- Brain delivery remains a major challenge for systemic administration
- Dual-pathway activation (MAPK + STAT3) could have complex effects in chronic administration
- Not commercially available as a research peptide from most suppliers
Research Dosage References
- <strong>Intracerebroventricular (animal studies)</strong> - 1-10 pmol - Single or repeated doses - ICV administration used in mouse studies. Active at extremely low (femtomolar to picomolar) concentrations. Systemic delivery and human dosing not established.
Mechanism of Action
Colivelin activates two parallel neuroprotective cascades: (1) The ADNF-9 moiety binds to heat shock protein 60 (HSP60), which activates the MAPK/ERK1/2 pathway, promoting neuronal survival gene expression and synaptic protein synthesis; (2) The AGA-HNG17 (Humanin) moiety binds to the CNTF receptor complex (CNTFR/WSX-1/gp130 trimer), activating JAK2/STAT3 signaling and suppressing Bax translocation to mitochondria, thereby preventing cytochrome c release and caspase activation. The dual mechanism provides synergistic protection against amyloid-beta toxicity, oxidative stress, and excitotoxicity.
Legal Status
Research compound only; not approved for any clinical use.
Primary Sources
- Colivelin: a neuroprotective peptide that combines Humanin and ADNF-9 activities. Molecular Brain Research, 2005.
- Colivelin rescues cognitive deficits in triple transgenic Alzheimer mice. Journal of Neuroscience Research, 2009.